NgoJuni 29, 2017, uphuhliso Laipushutai, udidi I amayeza ezintsha kunye nophuhliso wentsebenziswano JYMed kunye Guangzhou Linkhealth Medical Technology Co., Ltd., yenze inkqubela ebonakalayo. IND isibhengezo Ichiza iye yamkelwa CFDA.
JYMed and Guangzhou Linkhealth Medical Technology Co., Ltd. bafikelela kwisivumelwano intsebenziswano ngo-2016 ukuphuhlisa ngokudibeneyo le mveliso in China. Iintlobo sele lisigqibile POC izifundo zonyango kwi-EU kunye zazuza iqondo elungileyo ukhuseleko kunye noxolelo. Zombini i-FDA kunye waphetha ukuqaphela ukuba le iintlobo kwenziwe isicelo unyango kwi I / umgca II, yaye into ephambili iza kunikwa uncedo kunye nonyango kwezigulane nokulolonga sisilonda sikabhobhosi kulandelelo kumalingo onyango lwe CFDA.
okwenziwa sisilonda sikabhobhosi (UC) yi esingapheliyo, non-ngqo isifo yokukrala okwenzeka isikali kunye colon. Ngokutsho manani, izinga izehlo ka-UC na amatyala 1.2 20.3 / 100,000 umntu ngonyaka ngamnye kunye nokwanda kwe UC na amatyala 7.6 ukuya 246,0 / abantu 10,000 ngonyaka ngamnye. Iziganeko UC ixhaphake kakhulu kubantu abadala abasebatsha. Imarike UC iye ngezinga elikhulu kunye nemfuno iziyobisi, kwaye ziya kuqhubeka ukugcina oku kukhula eliphezulu kwixesha elizayo. Ukuza kuthi ga ngoku, ichiza UC-line yokuqala ikakhulu kusekelwe mesalazine kunye iihomoni, kunye neziyobisi lodidi lwesibini ziquka immunosuppressants kunye antibodies zebhayoloji monoclonal. Mesalazine uba umthamo intengiso-1 billion e-China kunye US $ 2 billion eUnited States ngowe-2015 Laipushutai na impendulo engcono beneempawu UC, yaye ekhuselekileyo ngaphezu amachiza-umgca wokuqala yangoku. It has a inzuzo elungileyo kwimarike kwaye kulindeleke ukuba ibe lodidi lokuqala UC iziyobisi.
ixesha Post: Mar-02-2019
